Arcadia Biosciences
RKDA
12 hedge funds and large institutions have $159K invested in Arcadia Biosciences in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 1 closing their positions.
8% less funds holding
Funds holding: 13 → 12 (-1)
10.32% less ownership
Funds ownership: 14.6% → 4.27% (-10%)
71% less capital invested
Capital invested by funds: $538K → $159K (-$379K)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$350K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$19.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.54K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$352 |
| 5 |
Morgan Stanley
New York
|
-$25 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $110K | -$350K | -85,508 | -72% |
|
2
State Street
Boston,
Massachusetts
| $40.3K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $7.75K | -$2.54K | -620 | -21% |
|
|
4
Morgan Stanley
New York
| $693 | -$25 | -6 | -3% |
|
5
BlackRock
New York
| $127 | – | – | – |
|
|
6
Group One Trading
Chicago,
Illinois
| $60 | -$352 | -86 | -83% |
|
|
7
Wells Fargo
San Francisco,
California
| $27 | +$8 | +2 | +33% |
|
8
US Bancorp
Minneapolis,
Minnesota
| $17 | – | – | – |
|
|
OLVIG
9
Oliver Lagore Vanvalin Investment Group
Flint,
Michigan
| $13 | – | – | – |
|
|
HI
10
Harbour Investments
Madison,
Wisconsin
| $3 | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$19.4K | -5,010 | Closed |
|
12
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$8 | -2 | -50% |
|
RKDA Hedge Fund Activity: Q3 2023 in Review
12 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q3 2023, worth a combined $159K — down 71% from $538K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RKDA and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 1 added.
The largest buyer was Wells Fargo, adding an estimated $8. The largest seller was Sabby Management, cutting an estimated $350K.
- 12 institutional investors held Arcadia Biosciences (RKDA) as of Q3 2023, down from 13 in Q2 2023.
- Funds reported $159K of Arcadia Biosciences stock for Q3 2023, down 71% quarter-over-quarter.
- 0 funds opened new Arcadia Biosciences positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest Arcadia Biosciences buyer in Q3 2023 was Wells Fargo, an estimated $8 added.
- The largest Arcadia Biosciences seller in Q3 2023 was Sabby Management, an estimated $350K sold.
Based on aggregated 13F filings for Q3 2023.